A human platelet lysate preparation that contains human plasma is provided. This preparation can be generated from human platelets by concentrating and washing them under defined conditions to control the degree of human plasma present. The washed platelet concentrate is then subjected to a freeze-thaw cycle to produce platelet lysate which is centrifuged and filtered through 0.65μ, 0.45μ and 0.2μ filters, aliquoted and stored frozen at <−20° C. until thawed for use. This invention describes the novel finding that the controlled addition of human plasma to the lysate preparation significantly enhances the cell growth potency of the lysate preparation. This lysate can be used as a media supplement to replace fetal bovine serum (FBS) or other non-human serum additives used for the culture of mammalian cells. This invention also describes the formulation and use of the lysate preparation as a topical application for skin care, and wound healing, including anti-wrinkling, anti-scarring and wound resolution applications of the invention.

A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

The present invention relates to platelet-rich plasma (PRP) for epicutaneous use in a wide range of applications in the cosmetic and dermatological fields and to a functional bioactive composition suitable for topical use, which comprises said PRP and allows complete absorption into the skin, hair or scalp, and which has a regenerating action for relaxing expression wrinkles, a lifting effect for sustaining relaxed skin tissues, for scar reduction and wound healing. The present composition performs a regenerating and a repairing action on the skin cell layers, combining the benefits of increasing vitality and longevity of the skin, scalp and hair follicle, without the disadvantages of invasive techniques. The present composition is formulated to allow complete absorption of the PRP and guarantees the vital function of platelet growth factors while combining a gradual, more physiological releasing rate, and stimulating the recruiting of stem cells.

The invention relates to a method for producing blood meal comprising the subsequent steps of (i) providing an aqueous mixture comprising raw blood, preferably having a solid content of between about 5 and about 18 wt %, and (ii) increasing the solid content of the mixture to obtain a mixture having a solid content of about 20 wt % or higher, preferably between about 20-80 wt % and (iii) concurrently drying and grinding the resultant mixture in an air turbulence mill, to obtain blood meal having an average particle size (d50) between 20 m and 0.7 mm, a d90 of below 1 mm as measured with laser diffraction using a dry powder Beckman Coulter particle size analyzer, and an ileal digestibility of about 85% or higher preferably of about 87% or higher, and more preferably about 90% or higher. The invention furthermore relates to a coagulated blood meal product with high ileal digestibility.

Disclosed herein are compositions, methods, and systems for treating skin damage or signs of aging in a subject including obtaining whole blood from the subject, collecting platelet rich plasma (PRP) from the whole blood, forming a first topical formulation having the PRP, providing the first topical formulation to the subject for application to an area of skin damage on the subject, providing a second topical formulation to the subject having an activator such that when the second topical formulation is applied to the area of skin damage on top of the first formulation, the PRP is activated and growth factors are released into the area of skin damage. Systems and kits useful in performing the methods are also disclosed.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

A method for producing high-concentration stem cell exosomes with enhanced anti-inflammatory function using Lipopolysaccharide (LPS) and/or Lipoteichoic Acid (LTA), as well as anti-inflammatory and/or regenerative compositions that can be produced by the aforementioned method are disclosed. The production method for the anti-inflammatory composition includes a first step of treating stem cells during cultivation with one or more selected from a group consisting of Lipopolysaccharide (LPS) and Lipoteichoic Acid (LTA), and optionally, a second step of separating stem cells, their culture medium, and/or their exosomes obtained as a result of the first step.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.

The present invention may provide a pharmaceutical composition for preventing or treating skin diseases, a cosmetic composition for preventing or improving skin diseases, and a stem cell therapeutic agent, which comprise an induced pluripotent stem cell-derived mesenchymal stem cell (iMSC), a culture thereof, or an exosome isolated from an iMSC or iMSC culture as active ingredients. When the composition of the present invention, etc. is used, it is possible to provide a composition for improving, preventing or treating skin diseases and a stem cell therapeutic agent which have an improved immunomodulating function over conventional mesenchymal stem cells.